Neutrophils drive type I interferon production and autoantibodies in patients with Wiskott-Aldrich syndrome
Karla Cervantes-Luévano(International Centre for Genetic Engineering and Biotechnology), Federica Benvenuti(International Centre for Genetic Engineering and Biotechnology), Marita Bosticardo(National Institutes of Health), Luigi D. Notarangelo(Harvard University), Elena Fontana(Institute of Genetic and Biomedical Research), Maria Pia Cicalese(Vita-Salute San Raffaele University), Alessandro Aiuti(University of Rome Tor Vergata), Paolo Uva(Environment Park), Genni Enza Marcovecchio(Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele), Maria Carmina Castiello(Institute of Genetic and Biomedical Research), Anna Villa(Institute of Genetic and Biomedical Research), Giulia Maria Piperno(International Centre for Genetic Engineering and Biotechnology), Asma Naseem(Great Ormond Street Hospital), Nicoletta Caronni(The San Raffaele Telethon Institute for Gene Therapy)
Cited by 26
Related Papers
Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome
|Science|2013|1k
Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency
|New England Journal of Medicine|2009|1k
The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM
|Nature|1998|942
Immune dysregulation in human subjects with heterozygous germline mutations in <i>CTLA4</i>
|Science|2014|844
Osteopetrosis: genetics, treatment and new insights into osteoclast function
|Nature Reviews Endocrinology|2013|580